1. 122 PROGNOSTIC FACTORS OF INFECTIONS AND EFFECT OF PRIMARY ANTI-INFECTIOUS PROPHYLAXIS IN MDS PATIENTS TREATED WITH AZACITIDINE (AZA): A PROSPECTIVE STUDY. (April 2015) Authors: Sebert, M.; Aguilar, C.; Ades, L.; Chevret, S.; Lortholary, O.; Fenaux, P. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S63 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 123 AZACITIDINE (AZA) COMBINED WITH IDARUBICIN (IDA) IN HIGHER RISK MDS (HRMDS) – RESULTS OF A PHASE I/II STUDY BY THE GFM. Issue 1 (April 2015) Authors: Sebert, M.; Ades, L.; Stamatoullas, A.; Braun, T.; Delaunay, J.; de Renzis, B.; Jeddi, R.; Meddeb, B.; Berger, M. Hunault; Samey, B.; Chermat, F.; Chaffaut, C.; Chevert, S.; Fenaux, P. Journal: Leukemia research Issue: Volume 39:Issue 1(2015:Jan.) Page Start: S63 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 142 MOLECULAR PROGNOSTIC FACTORS IN HIGHER RISK MDS RECEIVING FIRST LINE AZACYTIDINE (AZA). Issue 1 (April 2015) Authors: Ades, L.; Renneville, A.; Marceau, A.; Sebert, M.; Braun, T.; Nibourel, O.; Preudhomme, C.; Fenaux, P. Journal: Leukemia research Issue: Volume 39:Issue 1(2015:Jan.) Page Start: S72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 87 A PHASE II STUDY OF THE EFFICACY AND SAFETY OF AN INTENSIFIED SCHEDULE OF AZACITIDINE IN HIGHER RISK MDS PATIENTS: A STUDY BY THE GFM. (April 2015) Authors: Ades, L.; Guerci-Bresler, A.; Makhoul, P. Cony; Legros, L.; Delaunay, J.; Recher, C.; Sebert, M.; Lejeune, J.; Chevret, S.; Fenaux, P. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S44 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Efficacy of eculizumab against Eosinophilic Fasciitis associated with Paroxysmal Nocturnal Haemoglobinuria. (12th July 2016) Authors: Frumholtz, L.; Sebert, M.; de Masson, A.; Attias, P.; Ades, L.; Roux, J.; Jachiet, M.; Cabannes‐Hamy, A.; Elena Noguera, M.; Attencourt, C.; Bagot, M.; Socié, G.; Rybojad, M.; de La Tour, R. Peffault; Bouaziz, J.D. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 31:Number 2(2017) Page Start: e101 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients. (1st March 2022) Authors: Georgin‐Lavialle, S.; Terrier, B.; Guedon, A.F.; Heiblig, M.; Comont, T.; Lazaro, E.; Lacombe, V.; Terriou, L.; Ardois, S.; Bouaziz, J.‐D.; Mathian, A.; Le Guenno, G.; Aouba, A.; Outh, R.; Meyer, A.; Roux‐Sauvat, M.; Ebbo, M.; Zhao, L.P.; Bigot, A.; Jamilloux, Y. Journal: British journal of dermatology Issue: Volume 186:Number 3(2022) Page Start: 564 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients. (28th November 2021) Authors: Georgin‐Lavialle, S.; Terrier, B.; Guedon, A.F.; Heiblig, M.; Comont, T.; Lazaro, E.; Lacombe, V.; Terriou, L.; Ardois, S.; Bouaziz, J.‐D.; Mathian, A.; Le Guenno, G.; Aouba, A.; Outh, R.; Meyer, A.; Roux‐Sauvat, M.; Ebbo, M.; Zhao, L.P.; Bigot, A.; Jamilloux, Y. Journal: British journal of dermatology Issue: Volume 186:Number 3(2022) Page Start: 564 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P374: BLINATUMOMAB AS CONSOLIDATION FOR ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA. A REAL-WORLD STUDY. (23rd June 2022) Authors: Urbino, I.; Lengline, E.; Cerrano, M.; Rabian, F.; Kim, R.; Sebert, M.; Itzykson, R.; Audisio, E.; Ades, L.; Dombret, H.; Raffoux, E.; Ferrero, D.; Clappier, E.; Boissel, N. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 274 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Results of a Phase II Study of Guadecitabine in Higher Risk MDS Patients Refractory to or Relapsing after Azacitidine Treatment. (April 2017) Authors: Sebert, M.; Bally, C.; Peterlin, P.; Beyne-Rauzy, O.; Legros, L.; Gourin, M.P.; Sanhes, L.; Wattel, E.; Gyan, E.; Park, S.; Stamatoullas, A.; Laribi, K.; Banos, A.; Jueliger, S.; Chevret, S.; Ades, L.; Fenaux, P. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Topic: AS08-Treatment/AS08g-Clinical trials - Phase II-III: APR 246 PLUS AZACITIDINE (AZA) IN TP53 MUTATED (M) MDS AND AML. LONG TERM FOLLOW UP OF PHASE 2 STUDY BY THE GFM. (September 2021) Authors: Cluzeau, T.; Sebert, M.; Rahmé, R.; Cuzzubbo, S.; Walter-Petrich, A.; Peterlin, P.; Recher, C.; Stamatoullas, A.; Willems, L.; Raffoux, E.; Berthon, C.; Sallman, D.; Ades, L.; Fenaux, P. Journal: Leukemia research Issue: Volume 108(2021)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗